| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9126931 | HOFFMANN-LA ROCHE | Tetracyclic compound |
May, 2031
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9440922 | HOFFMANN-LA ROCHE | Tetracyclic compound |
Jun, 2030
(6 years from now) | |
| US9365514 | HOFFMANN-LA ROCHE | Composition comprising tetracyclic compound |
Mar, 2032
(7 years from now) | |
| US10350214 | HOFFMANN-LA ROCHE | Preparation containing tetracyclic compound at high dose |
Apr, 2035
(11 years from now) | |
| US11433076 | HOFFMANN-LA ROCHE | Preparation containing tetracyclic compound at high dose |
Apr, 2035
(11 years from now) | |
Alecensa is owned by Hoffmann-La Roche.
Alecensa contains Alectinib Hydrochloride.
Alecensa has a total of 5 drug patents out of which 0 drug patents have expired.
Alecensa was authorised for market use on 11 December, 2015.
Alecensa is available in capsule;oral dosage forms.
Drug patent challenges can be filed against Alecensa from 12 December, 2019.
The generics of Alecensa are possible to be released after 24 April, 2035.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-159) | Nov 06, 2024 |
| New Indication(I-756) | Nov 06, 2020 |
| Orphan Drug Exclusivity(ODE-105) | Dec 11, 2022 |
| Orphan Drug Exclusivity(ODE) | Nov 06, 2024 |
| New Chemical Entity Exclusivity(NCE) | Dec 11, 2020 |
Drugs and Companies using ALECTINIB HYDROCHLORIDE ingredient
NCE-1 date: 12 December, 2019
Market Authorisation Date: 11 December, 2015
Treatment: NA
Dosage: CAPSULE;ORAL
How can I launch a generic of ALECENSA before it's drug patent expiration?
More Information on Dosage
ALECENSA family patents
